I'm diabetic. I'd rather risk my shared health data being stolen than a double amputation

You want my medical records? Good, take them – now find me a cure

Register debate Welcome to the latest Register Debate in which writers and experts go head to head on technology topics, and you – the reader – choose the winning argument. The format is simple: we propose a motion, the arguments for the motion will run this Monday and Wednesday, and the arguments against on Tuesday and Thursday.

During the week you can cast your vote on which side you support using the poll embedded below, choosing whether you're in favour or against the motion. The final score will be announced on Friday, revealing whether the for or against argument was most popular. It's up to our writers to convince you to vote for their side.

This week’s motion is: Assumed consent is the right approach for sharing healthcare patients’ data, beyond their direct care. Or to put it another way: patient records should be shared with medical researchers on an opt-out basis.

The debate around the benefits of sharing medical data for the greater good versus individual’s expectations of confidentiality and consent, has become heated to say the least over the last year and a half. But if consent is not just assumed, but informed, do we all stand to benefit? Our contributors serve up their own prescriptions, but you get to decide.

Our second contributor arguing FOR THE MOTION is Dominic Nutt, a patient advocate and health campaigner specialising in new approaches to medical trials and driving medical innovation. He has been a type 1 diabetic for 40 years and is a rare cancer patient.

Our data is already bought and sold for profit. And we love it. Whenever we send an email, interact with our “free” social media accounts, when we walk down the street, through a shopping centre or log on in a coffee shop, our data is grabbed. We give it up for free Wi-Fi. As technophiles, I know most of you will be ahead of the game. But the vast majority of us don’t bother to argue, bought off by getting free access to a digital world. We don’t, for the most part, anonymise ourselves with VPNs nor opt out of marketing cookies.

We prostitute ourselves for a quick digital thrill with little real benefit. Nothing to write home about, anyway. But we pay a huge price – our very democracy has been rattled to the foundations with our data used to manipulate voters. But so what? I got a free email address!

Sharing our health data, which, unlike our digital data, will be automatically cleaned, will revolutionise our healthcare. It will change the way research – currently based on the diminishing returns of randomised clinical trials – takes place.

I am a type-1 diabetic. My antibodies attacked cells on my pancreas. I was also diagnosed with a rare cancer, which, if – or more likely when – it comes back it will be incurable.

Most of us who die from a cancer will die from a rare one that relies on old and failed treatments. But big pharma tends to ignore these orphan diseases. Why bother when so few patients – customers – will get the disease? There is no market.

So very little research that will lead to new therapeutics is carried out into rare diseases.

And what about common and chronic diseases – dementia, depression, heart disease, and pretty much any condition associated with senescence? Most of us are going to get old, after all.

There is a new movement in medical research to repurpose cheap drugs that are already in existence. Two examples are bisphosphonates – currently used to mitigate the effects of osteoporosis – and metformin, used to treat type-2 diabetics.

Yet they show genuine promise beyond their current purposes for decreasing the global incidence of a host of common diseases, including a range of cancers, heart disease, and neurodegenerative conditions.

Both are as cheap as chips because they no longer have intellectual property (IP) protection. As a result no big pharma company will invest in researching new uses for these old drugs, because without IP rights there is no profit to be made.

Public sector researchers – universities, for example – are also stymied. To carry out research on the effects of a mass-use drug needs data from thousands, if not millions of people. They can’t afford to run such research.

Yet the data is out there. Millions of people already take these drugs and their data is sitting there waiting to be examined. At the stroke of a key, researchers could analyse the effects of these drugs and test whether there is a correlation between their usage and the prevalence of all these killer diseases.

At the stroke of a key, researchers could analyse the effects of these drugs and test whether there is a correlation between their usage and the prevalence of all these killer diseases

And when it comes to rare diseases, researchers can use data to elicit what innovations have taken place at a local level and derive proofs of concept to test further any new interventions that may make a difference in outcomes.

So data sharing works at both the mass disease and rare disease ends of the spectrum.

I’m already sharing my data. Many type-1 insulin dependent diabetics are running a patient-led hack. We combine our insulin pumps which have a Bluetooth facility, with our constant glucose monitoring (CGM) systems. Our CGMs read our blood glucose levels allowing us to see what our scores are and to adjust manually our insulin doses in real time. It’s time consuming and a constant worry – human error leads to life-threatening hypo- and hyperglycaemia.

But by working together, and sharing data, we techie diabetics (techa-betics or dia-techies? Trademark pending) have worked a hack whereby our CGMs automatically speak to our insulin pumps and adjust our doses for us, leaving us free to carry on as normal without having to intervene every five minutes. It’s changed my life. (For those in the know, my A1C has reduced from 6.2 per cent to 5.4 per cent in less than a year).

The risks are minimal. Yes, a research company wanting to save my life may need to buy my data. They may make a profit, too, as they do with all drugs. Good – have at it – find me a cure.

And the risks of someone stealing my health data (and doing what with it?) are infinitely less than the risks of going blind, living my last years on dialysis, and with a double amputation of my lower limbs (all very common effects of type-1 diabetes).

I have no truck with anyone telling me, from the position of perfect health, what is in my interests. And certainly not from anyone using Facebook or Gmail. We take calculated risks everyday, when we cross the road to buy food, when we walk down the street with our phone in our hand, when we get in a car. We do so because the benefits outweigh the potential harms. ®

Cast your vote below. We'll close the poll on Thursday night and publish the final result on Friday. You can track the debate's progress here.

JavaScript Disabled

Please Enable JavaScript to use this feature.

Similar topics

Other stories you might like

  • Lonestar plans to put datacenters in the Moon's lava tubes
    How? Founder tells The Register 'Robots… lots of robots'

    Imagine a future where racks of computer servers hum quietly in darkness below the surface of the Moon.

    Here is where some of the most important data is stored, to be left untouched for as long as can be. The idea sounds like something from science-fiction, but one startup that recently emerged from stealth is trying to turn it into a reality. Lonestar Data Holdings has a unique mission unlike any other cloud provider: to build datacenters on the Moon backing up the world's data.

    "It's inconceivable to me that we are keeping our most precious assets, our knowledge and our data, on Earth, where we're setting off bombs and burning things," Christopher Stott, founder and CEO of Lonestar, told The Register. "We need to put our assets in place off our planet, where we can keep it safe."

    Continue reading
  • Conti: Russian-backed rulers of Costa Rican hacktocracy?
    Also, Chinese IT admin jailed for deleting database, and the NSA promises no more backdoors

    In brief The notorious Russian-aligned Conti ransomware gang has upped the ante in its attack against Costa Rica, threatening to overthrow the government if it doesn't pay a $20 million ransom. 

    Costa Rican president Rodrigo Chaves said that the country is effectively at war with the gang, who in April infiltrated the government's computer systems, gaining a foothold in 27 agencies at various government levels. The US State Department has offered a $15 million reward leading to the capture of Conti's leaders, who it said have made more than $150 million from 1,000+ victims.

    Conti claimed this week that it has insiders in the Costa Rican government, the AP reported, warning that "We are determined to overthrow the government by means of a cyber attack, we have already shown you all the strength and power, you have introduced an emergency." 

    Continue reading
  • China-linked Twisted Panda caught spying on Russian defense R&D
    Because Beijing isn't above covert ops to accomplish its five-year goals

    Chinese cyberspies targeted two Russian defense institutes and possibly another research facility in Belarus, according to Check Point Research.

    The new campaign, dubbed Twisted Panda, is part of a larger, state-sponsored espionage operation that has been ongoing for several months, if not nearly a year, according to the security shop.

    In a technical analysis, the researchers detail the various malicious stages and payloads of the campaign that used sanctions-related phishing emails to attack Russian entities, which are part of the state-owned defense conglomerate Rostec Corporation.

    Continue reading
  • FTC signals crackdown on ed-tech harvesting kid's data
    Trade watchdog, and President, reminds that COPPA can ban ya

    The US Federal Trade Commission on Thursday said it intends to take action against educational technology companies that unlawfully collect data from children using online educational services.

    In a policy statement, the agency said, "Children should not have to needlessly hand over their data and forfeit their privacy in order to do their schoolwork or participate in remote learning, especially given the wide and increasing adoption of ed tech tools."

    The agency says it will scrutinize educational service providers to ensure that they are meeting their legal obligations under COPPA, the Children's Online Privacy Protection Act.

    Continue reading
  • Mysterious firm seeks to buy majority stake in Arm China
    Chinese joint venture's ousted CEO tries to hang on - who will get control?

    The saga surrounding Arm's joint venture in China just took another intriguing turn: a mysterious firm named Lotcap Group claims it has signed a letter of intent to buy a 51 percent stake in Arm China from existing investors in the country.

    In a Chinese-language press release posted Wednesday, Lotcap said it has formed a subsidiary, Lotcap Fund, to buy a majority stake in the joint venture. However, reporting by one newspaper suggested that the investment firm still needs the approval of one significant investor to gain 51 percent control of Arm China.

    The development comes a couple of weeks after Arm China said that its former CEO, Allen Wu, was refusing once again to step down from his position, despite the company's board voting in late April to replace Wu with two co-chief executives. SoftBank Group, which owns 49 percent of the Chinese venture, has been trying to unentangle Arm China from Wu as the Japanese tech investment giant plans for an initial public offering of the British parent company.

    Continue reading
  • SmartNICs power the cloud, are enterprise datacenters next?
    High pricing, lack of software make smartNICs a tough sell, despite offload potential

    SmartNICs have the potential to accelerate enterprise workloads, but don't expect to see them bring hyperscale-class efficiency to most datacenters anytime soon, ZK Research's Zeus Kerravala told The Register.

    SmartNICs are widely deployed in cloud and hyperscale datacenters as a means to offload input/output (I/O) intensive network, security, and storage operations from the CPU, freeing it up to run revenue generating tenant workloads. Some more advanced chips even offload the hypervisor to further separate the infrastructure management layer from the rest of the server.

    Despite relative success in the cloud and a flurry of innovation from the still-limited vendor SmartNIC ecosystem, including Mellanox (Nvidia), Intel, Marvell, and Xilinx (AMD), Kerravala argues that the use cases for enterprise datacenters are unlikely to resemble those of the major hyperscalers, at least in the near term.

    Continue reading

Biting the hand that feeds IT © 1998–2022